Test Price
2,800 AEDโ Home Collection Available
LAMA3 Gene Laryngo-Onycho-Cutaneous Syndrome (LOCS) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
- 99.9% Diagnostic Sensitivity โ Next-Generation Sequencing (NGS) validated under ISO 9001:2015 Certified Laboratory (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics โ VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection, available daily from 8 AM to 11 PM.
- Telephonic Post-Test Clinical Guidance โ Board-certified Medical Genetics consultant session included to clarify result implications.
- Direct Insurance Billing Verification via WhatsApp +971 54 548 8731.
This advanced genetic test provides comprehensive analysis of the LAMA3 gene using NGS to definitively diagnose Laryngo-Onycho-Cutaneous Syndrome, enabling early family screening and structured cancer surveillance planning.
Test Overview & Methodology
This advanced genetic test analyzes the LAMA3 gene via Next-Generation Sequencing (NGS) to definitively diagnose Laryngo-Onycho-Cutaneous Syndrome (LOCS), a rare autosomal recessive genodermatosis characterized by skin fragility, nail dystrophy, laryngeal granulation tissue, and a significantly elevated risk of squamous cell carcinoma. The assay identifies pathogenic mutations across all coding exons and flanking intronic regions, including small variants, deletions, and duplications that would be missed by targeted methods.
| Parameter | Our NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | 99.9% analytical sensitivity / specificity | Limited to pre-targeted variants; ~95% |
| Methodology | NGS (full-gene coverage with CNV detection) | Sanger (exon-by-exon, slow) |
| Speed | 3โ4 weeks | 8โ12 weeks |
Physician Insight & Safety Protocols
"As a Consultant Medical Genetics specialist, I recognize the uncertainty a suspected diagnosis of Laryngo-Onycho-Cutaneous Syndrome can create for patients and families. This NGS test delivers the molecular clarity required to guide surveillance strategies and inform at-risk relatives, yet the result must always be interpreted within your full clinical context. I strongly advise against making medical decisions based solely on this genetic finding without a comprehensive evaluation."
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Critical Advisory โ Medication Safety
Do not discontinue any prescribed medication, topical therapy, or dermatological regimen without direct consultation with your supervising physician. Genetic test results complement but do not replace ongoing clinical care. Always maintain coordination with your treating dermatologist and oncologist.
Exclusion Criteria & Emergency Red Flags
- Sample rejection: DNA samples with severe degradation, insufficient quantity, or known hematopoietic neoplasm contamination (potential somatic mosaicism confound).
- Not indicated for: Somatic (acquired) variants in tumour tissue; this is a germline constitutional test only.
- Seek Emergency Care if you experience sudden stridor, hoarseness with dyspnoea, or rapid airway compromise โ these may signal acute laryngeal granulation worsening in LOCS.
Patient FAQ & Clinical Guidance
1. What does the LAMA3 genetic test detect?
This test identifies pathogenic mutations in the LAMA3 gene that cause Laryngo-Onycho-Cutaneous Syndrome, enabling accurate diagnosis, family screening, and cancer surveillance planning. The NGS approach sequences all coding exons and flanking intronic regions, detecting small variants, deletions, and duplications that would be missed by targeted methods.
2. How is the test performed and what sample is needed?
A simple peripheral blood draw, extracted DNA, or a single drop of blood on an FTA card can be collected via a hospital-grade home visit. The sample is transported in ISO-certified cold-chain conditions to our DHA-licensed genomics laboratory, where DNA is extracted, libraries are prepared, and NGS is performed with bioinformatic analysis.
3. Are there any special preparations or legal considerations?
No fasting or medication adjustments are required. However, a pre-genetic counselling session is mandatory to draw a pedigree of affected family members and obtain informed consent, in strict compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability and the UAE Personal Data Protection Law. All data is anonymised and stored on secure UAE-based servers.
4. How long does it take to receive the results?
The standard turnaround time is 3โ4 weeks from sample receipt. This allows for DNA extraction, library preparation, NGS sequencing, bioinformatic analysis, variant interpretation, and medical genetics review. You will receive a comprehensive report accompanied by a telephonic interpretation session.
5. What is the cost and are there additional fees?
The test is priced at 2,800 AED, inclusive of the NGS analysis, bioinformatic interpretation, and the post-test physician consultation. Home collection logistics and courier retrieval are included at no extra charge. Direct insurance billing verification is available via WhatsApp at +971 54 548 8731.
UAE Regulatory & Data Privacy Adherence
We operate under the highest standards of UAE regulatory compliance, ensuring your genetic data is protected by law.
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) โ mandates de-identification, consent, and secure storage of all personal health information.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields โ governs digital health data transmission and telemedicine frameworks.
- Federal Decree-Law No. 4 of 2016 on Medical Liability โ establishes the legal standards for clinical testing, patient consent, and physician accountability.
ISO 9001:2015 Certified Facility | Cert: INT/EGQ/2509DA/3139 | DHA Facility License: 1143 | Corporate Lab: DNA Labs UAE | Address: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE
Clinical & Logistical Metadata
| Test Name | LAMA3 Gene Laryngo-Onycho-Cutaneous Syndrome (LOCS) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3โ4 weeks |
| Sample Type / Matrix | Peripheral Blood, Extracted DNA, or FTA Card Blood Spot |
| Methodology Used | Next-Generation Sequencing (NGS), Full-Gene Coverage with CNV Detection |
| ICD-10-CM Code | Q81.8 |
| LOINC Code | 82319-3 |
| DHA Facility License & Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians